Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6)

Status unconfirmed · Phase 1 · Has a placebo group

Conditions studied: Influenza

In brief

The purpose of this study is to determine the safety and tolerability of the anti-TSG101 human monoclonal antibody (FGI-101-1A6)when administered intravenously to healthy volunteers.

Key facts

Study ID

NCT01299142

Run by

Functional Genetics Inc.

People needed

48

Starts

2011-01-01

Expected to finish

2011-10-01

Last updated by the study team

2011-02-18

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy volunteers ages 18-45
• Normal laboratory (blood tests) results

You may not qualify if…

• Prior immunization with live-attenuated vaccines

Where it is running

• SNBL Clinical Pharmacology Center — Baltimore, Maryland, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.